keyword
MENU ▼
Read by QxMD icon Read
search

Pet psma

keyword
https://www.readbyqxmd.com/read/28525451/metastases-from-colorectal-cancer-avid-on-68ga-psma-pet-ct
#1
Lise Hangaard, Mads Ryø Jochumsen, Mikkel Holm Vendelbo, Kirsten Bouchelouche
Ga-PSMA PET/CT is currently used for detection of prostate cancer including metastases, even at low prostate-specific antigen values. A grown number of reports have shown increased uptake of PSMA in neovessels of nonprostatic malignancies including lung cancer, and recently a case report has demonstrated increased PSMA uptake in colorectal adenocarcinoma. In this case report, we demonstrate increased Ga-PMSA uptake on PET/CT in metastases from previously treated colon adenocarcinoma, and it illustrates the importance of histology of suspicious lesions on Ga-PSMA PET/CT...
May 19, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28522741/impact-of-ga-68-psma-11-pet-on-management-in-patients-with-biochemically-recurrent-prostate-cancer
#2
Thomas A Hope, Rahul Aggarwal, Bryant Chee, Dora Tao, Kirsten L Greene, Matthew Cooperberg, Felix Feng, Albert Chang, Charles J Ryan, Eric J Small, Peter R Carroll
Purpose: The purpose of this prospective study was to estimate the effect of (68)Ga-prostate specific membrane antigen (PSMA)-11 PET on intended management of patients with biochemically recurrent prostate cancer. Methods: Pre- and post-imaging surveys were filled out by referring providers in patients with biochemical recurrence who were imaged using (68)Ga-PSMA-11 PET. Inclusion criteria for this study required a PSA doubling time of less than 12 months after initial treatment (NCT02611882). Of the 150 consecutive patients imaged, 126 surveys were completed (84% response rate)...
May 18, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28522740/initial-experience-with-volumetric-68-ga-psma-i-t-pet-ct-for-assessment-of-whole-body-tumor-burden-as-a-quantitative-imaging-biomarker-in-patients-with-prostate-cancer
#3
Sebastian Schmuck, Christoph A von Klot, Christoph Henkenberens, Jan M Sohns, Hans Christiansen, Hans-Jürgen Wester, Tobias L Ross, Frank M Bengel, Thorsten Derlin
A quantitative imaging biomarker is desirable to provide a comprehensive measure of whole-body tumor burden in patients with metastatic prostate cancer, and to standardize the evaluation of treatment-related changes. Therefore, we evaluated whether prostate specific membrane antigen (PSMA) ligand positron emission tomography/computed tomography (PET/CT) may be applied to provide PSMA-derived volumetric parameters for quantification of whole-body tumor burden. Methods: 101 patients who underwent a (68)Ga-PSMA I&T PET/CT because of increasing prostate specific antigen (PSA) levels after radical prostatectomy were included in this retrospective analysis...
May 18, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28522176/re-diagnostic-accuracy-of-ga-68-hbed-cc-psma-ligand-pet-ct-before-salvage-lymph-node-dissection-for-recurrent-prostate-cancer
#4
Boris Hadaschik, Ken Herrmann
No abstract text is available yet for this article.
May 15, 2017: European Urology
https://www.readbyqxmd.com/read/28511221/-psma-radioguided-surgery-for-salvage-lymphadenectomy-in-recurrent-prostate-cancer
#5
Isabel Rauscher, Matthias Eiber, Tobias Maurer
Recently, the use of (111)In-labeled PSMA-I&T-based radioguided surgery ((111)In-PSMA(-)RGS) for salvage surgery using intraoperative ex-vivo γ-probe measurements has been described by our group as a promising new and individual treatment concept in patients with localised recurrent prostate cancer (PC). (111)In-PSMA-RGS allowed for the intraoperative identification of metastatic lesions with a sensitivity, specificity and accuracy of 92.3, 93.5 and 93.1%, respectively, compared to histopathology. (111)In-PSMA-RGS was able to detect 5 additional lymph node metastases in 3 out of 31 patients compared to (68)Ga-HBED-CC-PSMA PET...
April 2017: Aktuelle Urologie
https://www.readbyqxmd.com/read/28511220/-significance-and-value-of-psma-ligands-in-prostate-cancer
#6
Claudia Gasch, Stefan Körber, Christophe Kremer, Matthias Eiber, Clemens Kratochwil, Uwe Haberkorn, Markus Hohenfellner, Boris Hadaschik, Frederik L Giesel
In recent years, PSMA-targeting PET tracers such as (68)Ga-PSMA-11 have shown promising results, thus contributing to a better management of prostate cancer patients. At the present time, (68)Ga-PSMA-11 is most frequently used for diagnostic evaluation in the setting of biochemical recurrence of prostate cancer. In this context, the (68)Ga-PSMA-11 PET/CT delivers superior detection rates compared to conventional imaging, especially for the detection of small, unsuspicious lesions or lesions in the presence of low PSA values...
April 2017: Aktuelle Urologie
https://www.readbyqxmd.com/read/28508120/effects-of-arm-truncation-on-the-appearance-of-the-halo-artifact-in-68-ga-psma-11-hbed-cc-pet-mri
#7
Ali Afshar-Oromieh, Maya Wolf, Uwe Haberkorn, Marc Kachelrieß, Regula Gnirs, Klaus Kopka, Heinz-Peter Schlemmer, Martin T Freitag
PURPOSE: PSMA ligand imaging with hybrid PET/MRI scanners could be an integral part of the clinical routine in the future. However, the first study about this novel method revealed a severe photopenic artifact ("halo artifact") around the urinary bladder causing significantly reduced tumor visibility. The aim of this evaluation was to analyze the role of arm truncation on the appearance of the halo artifact in (68)Ga-PSMA-11 PET/MRI hypothesizing that this influences the appearance. METHODS: Twenty-seven consecutive patients were subjected to (68)Ga-PSMA-11 PET/CT (1 h p...
May 15, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28499607/evaluation-of-intensity-modulated-radiation-therapy-dose-painting-for-localized-prostate-cancer-using-68-ga-hbed-cc-psma-pet-ct-a-planning-study-based-on-histopathology-reference
#8
Constantinos Zamboglou, Ilias Sachpazidis, Khodor Koubar, Vanessa Drendel, Rolf Wiehle, Simon Kirste, Michael Mix, Florian Schiller, Panayiotis Mavroidis, Philipp T Meyer, Martin Werner, Anca L Grosu, Dimos Baltas
PURPOSE: To demonstrate the feasibility and to evaluate the tumour control probability (TCP) and normal tissue complication probability (NTCP) of IMRT dose painting using (68)Ga-HBED-CC PSMA PET/CT for target delineation in prostate cancer (PCa). METHODS AND MATERIALS: 10 patients had PSMA PET/CT scans prior to prostatectomy. GTV-PET was generated on the basis of an intraprostatic SUVmax of 30%. Two IMRT plans were generated for each patient: Plan(77) which consisted of whole-prostate IMRT to 77Gy, and Plan(95) which consisted of whole-prostate IMRT to 77Gy and a simultaneous integrated boost to the GTV-PET up to 95Gy (35 fractions)...
May 9, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28497198/diagnostic-performance-of-68-ga-psma-11-hbed-cc-pet-ct-in-patients-with-recurrent-prostate-cancer-evaluation-in-1007-patients
#9
Ali Afshar-Oromieh, Tim Holland-Letz, Frederik L Giesel, Clemens Kratochwil, Walter Mier, Sabine Haufe, Nils Debus, Matthias Eder, Michael Eisenhut, Martin Schäfer, Oliver Neels, Markus Hohenfellner, Klaus Kopka, Hans-Ulrich Kauczor, Jürgen Debus, Uwe Haberkorn
PURPOSE: Since the clinical introduction of (68)Ga-PSMA-11 PET/CT, this imaging method has rapidly spread and is now regarded as a significant step forward in the diagnosis of recurrent prostate cancer (PCa). The aim of this study was to analyse the influence of several variables with possible influence on PSMA ligand uptake in a large cohort. METHODS: We performed a retrospective analysis of 1007 consecutive patients who were scanned with (68)Ga-PSMA-11 PET/CT (1 h after injection) from January 2014 to January 2017 to detect recurrent disease...
May 12, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28490470/metal-artifact-reduction-of-ct-scans-to-improve-pet-ct
#10
Charlotte S van der Vos, Anne Ij Arens, Jim Hamill, Christian Hofmann, Vladimir Y Panin, Antoi Pw Meeuwis, Eric P Visser, Lioe-Fee de Geus-Oei
In recent years different metal artifact reduction (MAR) methods have been developed for computed tomography (CT). These methods have only recently been introduced for positron emission tomography/computed tomography (PET/CT) even though they could be beneficial for interpretation, segmentation and quantification of the PET/CT images. In this study, phantom and patient scans were analyzed visually and quantitatively to measure the effect on PET images of iterative metal artifact reduction (iMAR) of CT data...
May 10, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28488027/fibrous-dysplasia-mimicking-bone-metastasis-on-68-ga-psma-pet-mri
#11
Liesbeth De Coster, Raf Sciot, Wouter Everaerts, Olivier Gheysens, Raf Verscuren, Christophe M Deroose, Steven Pans, Koen Van Laere, Karolien E Goffin
No abstract text is available yet for this article.
May 9, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28481797/incidental-prostate-specific-membrane-antigen-uptake-in-a-peripheral-nerve-sheath-tumor
#12
Shankar Vamadevan, Ken Le, Lily Shen, Leo Ha, Robert Mansberg
A 66-year-old man with recently diagnosed prostate cancer (Gleason score 9) was referred for Ga-prostate-specific membrane antigen (PSMA) PET/CT with prostate-specific antigen level of 7.5 μg/L. PET/CT demonstrated increased PSMA uptake (SUVmax 4.7) in a soft tissue density in the left adductor compartment. MRI and cytopathology of the biopsied soft tissue density was compatible with a peripheral nerve sheath tumor. This case illustrates that PSMA uptake can occur in a peripheral nerve sheath tumor and should be taken into consideration as a benign cause of PSMA uptake...
May 6, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28481793/in-vivo-demonstration-of-psma-expression-in-adenocarcinoma-urinary-bladder-using-68ga-psma-11-pet-ct
#13
Shambo Guha Roy, Girish Kumar Parida, Sarthak Tripathy, Abhinav Singhal, Madhavi Tripathi, Chandrasekhar Bal
In vitro and in vivo studies have demonstrated prostate-specific membrane antigen (PSMA) expression in various malignant and benign tumors. Based on the recent immunohistochemical study showing PSMA expression in adenocarcinoma of urinary bladder, we hypothesized that PSMA expression in adenocarcinoma of urinary bladder can be demonstrated in vivo using Ga-PSMA 11 PET/CT. We present a man with exstrophy bladder, presenting with adenocarcinoma urinary bladder referred for staging PET/CT. Both F-FDG and Ga-PSMA-11 PET/CT were done, which showed PSMA expression in the primary tumor as well as metastatic lymph nodes...
May 6, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28481791/a-comprehensive-safety-evaluation-of-68ga-psma-11-pet-ct-in-prostate-cancer-the-results-of-2-prospective-multicenter-trials
#14
Julie B Nielsen, Helle D Zacho, Uwe Haberkorn, Karin M Nielsen, Katja Dettmann, Niels C Langkilde, Lars J Petersen
PURPOSE: The aim of this study was to evaluate the clinical safety profile of the Ga-PSMA-11 ligand for PET/CT imaging in prospective clinical trials. METHODS: Eighty-eight patients with newly diagnosed or recurrent prostate cancer participated in 2 prospective trials. Safety reporting was identical in the 2 trials. The Ga-PSMA-11 ligand was administered as 2 MBq/kg body weight (mean, 9.2 μg, 9.7 nmol). The reporting of clinical adverse events (AEs) and the measurement of blood pressure (BP) and heart rate (HR) were performed prior to injection (baseline); immediately after injection of Ga-PSMA-11 (postinjection); at 1, 10, and 60 minutes after injection; and after acquisition of the PET/CT scan (postscan)...
May 6, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28481787/evaluation-of-practical-interpretation-hurdles-in-68ga-psma-pet-ct-in-55-patients-physiological-tracer-distribution-and-incidental-tracer-uptake
#15
Julian Kirchner, Benedikt Michael Schaarschmidt, Lino Morris Sawicki, Philipp Heusch, Hubertus Hautzel, Johannes Ermert, Robert Rabenalt, Gerald Antoch, Christian Buchbender
PURPOSE: To investigate the physiologic Ga-PSMA distribution and evaluate focal or diffuse radiotracer uptake in nonprostate cancer malignancies and in incidental findings. METHODS: Ga-PSMA PET/CT scans in 55 men performed for prostate cancer (49) or renal cell carcinoma (6) staging were analyzed retrospectively. Two radiologists evaluated the datasets in 2 reading sessions. First, physiological Ga-PSMA uptake was evaluated. Second, scans were analyzed for incidental uptake...
May 6, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28474140/comparison-of-psma-hbed-and-psma-i-t-as-diagnostic-agents-in-prostate-carcinoma
#16
Michael McCarthy, Tiffany Langton, Divesh Kumar, Andrew Campbell
PURPOSE: Gallium(68)-labelled prostate-specific membrane antigen (PSMA) radiopharmaceuticals can be used to detect prostate cancer (PCa) cells due the their over expression of PSMA. The (68)Ga HBED-PSMA (PSMA-HBED) ligand has been most widely used and can be considered the current gold standard agent. Further PSMA ligands based on the DOTAGA and DOTA conjugates have more recently been developed. These agents (PSMA-I&T and PSMA-617) have potential theranostic capabilities as they can be conjugated with therapeutic radioisotopes...
May 4, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28473595/intra-individual-comparison-of-18-f-psma-1007-pet-ct-multi-parametric-mri-and-radical-prostatectomy-specimen-in-patients-with-primary-prostate-cancer-a-retrospective-proof-of-concept-study
#17
Claudia Kesch, Maria Vinsensia, Jan P Radtke, Heinz P Schlemmer, Martina Heller, Elena Ellert, Tim Holland-Letz, Stefan Duensing, Nils Grabe, Ali Afshar-Oromieh, Kathrin Wieczorek, Martin Schäfer, Oliver C Neels, Jens Cardinale, Clemens Kratochwil, Markus Hohenfellner, Klaus Kopka, Uwe Haberkorn, Boris A Hadaschik, Frederik L Giesel
Background:(68)Ga-prostate-specific membrane antigen (PSMA)-11-positron-emission-tomography (PET)/ computer-tomography (CT) represents an advanced method for staging of primary prostate cancer (PCa) and diagnosis of recurrent or metastatic PCa. However, due to the narrow availability of (68)Ga the development of alternative tracers is of high interest. Objective: To examine the value of the new PET tracer (18)F-PSMA-1007 for staging of local disease by comparing it to multiparametric magnetic resonance imaging (mpMRI) and radical prostatectomy (RP) histopathology...
May 4, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28462154/an-explanatory-case-on-the-limitations-of-lymph-node-staging-in-recurrent-prostate-cancer
#18
Marco Bandini, Giorgio Gandaglia, Nicola Fossati, Francesco Montorsi, Alberto Briganti
We describe the case of a 54-year-old man with nodal recurrence prostate cancer after radical prostatectomy, salvage external-beam radiotherapy and salvage lymph node dissection. The patient was evaluated with a lymphotropic ultrasmall superparamagnetic particles of iron oxide (USPIO)-MRI and a (68)Ga radiolabelled prostate specific membrane antigen (Ga68-PSMA) PET-CT scan which enhanced persistent localized nodal disease. The patient was then considered for a second robot-assisted extended S-LND. Differently from preoperative imaging, pathology report revealed a wide nodal involvement mirroring a metastatic disease...
May 2017: Urology Case Reports
https://www.readbyqxmd.com/read/28461986/68ga-psma-pet-ct-imaging-in-recurrent-prostate-cancer-where-are-we-now
#19
REVIEW
Ewa Witkowska-Patena, Andrzej Mazurek, Mirosław Dziuk
INTRODUCTION: Prostate cancer (PCa) is a major health concern worldwide with up to 60% of patients experiencing biochemical relapse after radical treatment. Early diagnosis of PCa recurrence is of high importance for successful salvage therapy. The need for accurate imaging has prompted the introduction of prostate-specific membrane antigen (PSMA)-based radiotracers for positron emission tomography (PET). MATERIAL AND METHODS: In this review we summarized and discussed the results of the studies analyzing the utility of 68Ga-PSMA PET/CT in patients who experienced a biochemical relapse of prostate cancer...
2017: Central European Journal of Urology
https://www.readbyqxmd.com/read/28450569/-18-f-dcfpyl-pet-ct-in-the-detection-of-prostate-cancer-at-60-and-120-minutes-detection-rate-image-quality-activity-kinetics-and-biodistribution
#20
Maurits Wondergem, Friso van der Zant, Remco Knol, Sergiy Lazarenko, Jan Pruim, Igle Jan de Jong
Introduction: There is increasing interest in PET/CT with PSMA tracers for imaging of prostate cancer due to higher detection rates of prostate cancer lesions as compared to PET/CT with choline. For (68)Ga-PSMA-11 tracers, late imaging at 180 min post injection (p.i.) instead of imaging at 45-60 min p.i. improves detection of prostate cancer lesions. For (18)F-DCFPyL improved detection rates has recently been reported in a small pilot study. In this study, we report the effects of PET/CT imaging at 120 minutes p...
April 27, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
keyword
keyword
110902
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"